Massachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA.
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Nat Commun. 2023 Mar 21;14(1):1559. doi: 10.1038/s41467-023-37226-0.
Schwannomas are common sporadic tumors and hallmarks of familial neurofibromatosis type 2 (NF2) that develop predominantly on cranial and spinal nerves. Virtually all schwannomas result from inactivation of the NF2 tumor suppressor gene with few, if any, cooperating mutations. Despite their genetic uniformity schwannomas exhibit remarkable clinical and therapeutic heterogeneity, which has impeded successful treatment. How heterogeneity develops in NF2-mutant schwannomas is unknown. We have found that loss of the membrane:cytoskeleton-associated NF2 tumor suppressor, merlin, yields unstable intrinsic polarity and enables Nf2 Schwann cells to adopt distinct programs of ErbB ligand production and polarized signaling, suggesting a self-generated model of schwannoma heterogeneity. We validated the heterogeneous distribution of biomarkers of these programs in human schwannoma and exploited the synchronous development of lesions in a mouse model to establish a quantitative pipeline for studying how schwannoma heterogeneity evolves. Our studies highlight the importance of intrinsic mechanisms of heterogeneity across human cancers.
神经鞘瘤是常见的散发性肿瘤,也是家族性神经纤维瘤病 2 型 (NF2) 的标志,主要发生在颅神经和脊神经上。几乎所有的神经鞘瘤都是由于 NF2 肿瘤抑制基因失活引起的,只有少数(如果有的话)有协同突变。尽管神经鞘瘤具有遗传均一性,但它们表现出显著的临床和治疗异质性,这阻碍了成功的治疗。NF2 突变型神经鞘瘤中的异质性是如何发展的尚不清楚。我们发现,膜细胞骨架相关 NF2 肿瘤抑制因子 merlin 的缺失会导致内在极性不稳定,并使 Nf2 雪旺细胞采用不同的 ErbB 配体产生和极化信号程序,这表明存在雪旺细胞瘤异质性的自我生成模型。我们验证了这些程序的生物标志物在人类神经鞘瘤中的异质分布,并利用小鼠模型中病变的同步发展,建立了一个定量研究神经鞘瘤异质性演变的方法。我们的研究强调了内在异质性机制在人类癌症中的重要性。